北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 基础医学院  > 细胞生物学系  > 期刊论文
学科主题: 基础医学
题名:
Over-Expression of LAPTM4B is Associated With Poor Prognosis and Chemotherapy Resistance in Stages III and IV Epithelial Ovarian Cancer
作者: Yin, Mingzhu1; Li, Cong2; Li, Xia3; Lou, Ge1; Miao, Bing4; Liu, Xiaodong5; Meng, Fanling1; Zhang, Haiyu6; Chen, Xiuwei1; Sun, Meng6; Ling, Qiu7; Zhou, Rouli8
关键词: LAPTM4B ; epithelial ovarian carcinoma ; chemotherapy resistance ; survival
刊名: JOURNAL OF SURGICAL ONCOLOGY
发表日期: 2011-07-01
DOI: 10.1002/jso.21912
卷: 104, 期:1, 页:29-36
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Surgery
研究领域[WOS]: Oncology ; Surgery
关键词[WOS]: HEPATOCELLULAR-CARCINOMA ; OVEREXPRESSION ; SURVIVAL ; PROTEIN ; MARKER
英文摘要:

Background: The purpose of this study was to determine whether LAPTM4B over-expression is associated with the prognosis and chemotherapy resistance in patients with stages III and IV epithelial ovarian carcinoma, i.e., patients with peritoneal metastasis or lymph node metastasis of epithelial ovarian carcinoma. Methods: LAPTM4B expression was evaluated in 10 normal ovarian and 113 stages III-IV ovarian carcinomas specimens by Western blotting analyses and immunohistochemistry. Univariate and multivariate analyses were performed to determine the association between LAPTM4B expression and prognosis and the relationship between LAPTM4B over-expression and chemotherapy resistance.

Results: Western blotting analysis demonstrated that LAPTM4B was overexpressed in ovarian cancers, and immunohistochemistry results revealed that 80 patients were LAPTM4B over-expression. The five-year overall survival (OS) rates for patients with high LAPTM4B expression and low LAPTM4B expression were 27.36% and 90.7%, respectively (hazard ratio = 20.611, 95% CI: 5.916-71.808, P < 0.0001). The five-year progression-free survival (PFS) rate was 17.68% for patients in the high-expression group and 84.42% for patients in the low-expression group (hazard ratio = 17.852, 95% CI: 6.31-5.935, P < 0.0001); The presence of chemotherapy resistance was significantly associated with LAPTM4B expression (OR: 36.609, 95% CI: 4.737-282.941, P = 0.0006).

Conclusions: LAPTM4B over-expression is an independent factor in stages III-IV epithelial ovarian carcinoma prognosis and chemotherapy resistance, and it may be an important potential biomarker. J. Surg. Oncol. 2011;104:29-36. (C) 2011 Wiley-Liss, Inc.

语种: 英语
WOS记录号: WOS:000291347600006
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/50752
Appears in Collections:基础医学院_细胞生物学系_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Harbin Med Univ, Tumor Hosp, Dept Gynecol Oncol, Harbin 150081, Peoples R China
2.Harbin Med Univ, Tumor Hosp, Dept Pathol, Harbin 150081, Peoples R China
3.Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Harbin, Peoples R China
4.Chinese Med Hosp Harbin, Senior Officials Inpatient Ward, Harbin, Peoples R China
5.Harbin Med Univ, Dept Emergency Traumatol, Affiliated Hosp 2, Harbin 150081, Peoples R China
6.Harbin Med Univ, Dept Biostat, Harbin 150081, Peoples R China
7.Harbin Med Univ, Dept Microbiol, Harbin 150081, Peoples R China
8.Peking Univ, Dept Cell Biol, Sch Basic Med Sci, Beijing 100191, Peoples R China

Recommended Citation:
Yin, Mingzhu,Li, Cong,Li, Xia,et al. Over-Expression of LAPTM4B is Associated With Poor Prognosis and Chemotherapy Resistance in Stages III and IV Epithelial Ovarian Cancer[J]. JOURNAL OF SURGICAL ONCOLOGY,2011,104(1):29-36.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Yin, Mingzhu]'s Articles
[Li, Cong]'s Articles
[Li, Xia]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Yin, Mingzhu]‘s Articles
[Li, Cong]‘s Articles
[Li, Xia]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace